Oncoheroes Biosciences is proud to announce a significant milestone in its mission to combat pediatric brain cancer. In a recent paper published in SLAS Discovery journal titled "Development of a High-Throughput Screening Platform to Identify New Therapeutic Agents for Medulloblastoma Group 3" authored by Inés Fallon, Henar Hernando, Olga Almacellas-Rabaiget, Berta Marti-Fuster, Cesare Spadoni, Darell D Bigner, and Eva Méndez, our team reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children
Medulloblastoma presents a formidable challenge in oncology due to its resistance to traditional treatments. Oncoheroes recognizes that early selection of compounds that effectively target cancer cells while sparing normal tissues is crucial for success in clinical trials. Addressing this challenge head-on, we have engineered a screening platform designed to minimize toxicity risks and advance molecules with the highest likelihood of efficacy and safety for patients. Cesare Spadoni, Oncoheroes’ Chief Operating Officer and co-founder elaborates, "The development of this platform signifies a pivotal step forward in our quest to accelerate pediatric oncology drug development. By prioritizing safety and efficacy, we aim to accelerate the translation of scientific discoveries into life-saving therapies".
The publication of our research in SLAS Discovery marks a significant achievement for Oncoheroes. Inés Fallon, the first author of the paper, expresses our team's enthusiasm, stating, "We are thrilled to contribute to the body of knowledge surrounding pediatric brain tumors. This publication underscores our commitment to collaboration and innovation in the fight against childhood cancer".